Human neural progenitor cells retain viability, phenotype, proliferation, and lineage differentiation when labeled with a novel iron oxide nanoparticle, Molday ION Rhodamine B

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 4593-4600

  Shen, Wei Bin ^a,b   Plachez, Celine ^b   Chan, Amanda ^c   Yarnell, Deborah ^a   Puche, Adam C ^b   Fishman, Paul S ^a,b   Yarowsky, Paul ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c NOTRE DAME OF MARYLAND UNIVERSITY   (United States)

Author keywords

Ferumoxides; Human; MION; Neural stem cells; SC121 antibody; Toxicology; USPIO

Indexed keywords

BETA TUBULIN; GLIAL FIBRILLARY ACIDIC PROTEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; MOLDAY ION RHODAMINE B NANOPARTICLE; TRANSCRIPTION FACTOR SOX; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ANTIBODY LABELING; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL DIVISION; CELL LABELING; CELL LINEAGE; CELL MIGRATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CELL VIABILITY; FREEZE THAWING; GLIA CELL; HUMAN; IMMUNOCYTOCHEMISTRY; NEURAL STEM CELL; NONHUMAN; PHENOTYPE; STEM CELL CULTURE;

FERUMOXIDES; HUMAN; MION; NEURAL STEM CELLS; SC121 ANTIBODY; TOXICOLOGY; USPIO;

CELL PHYSIOLOGICAL PROCESSES; CELLS, CULTURED; COLORING AGENTS; HUMANS; MAGNETITE NANOPARTICLES; NEURAL STEM CELLS; PHENOTYPE; RHODAMINES; STAINING AND LABELING;

EID: 84888615677     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S53012     Document Type: Article

References (24)

1. Bhasin A, Padma Srivastava MV, etal. Stem cell therapy: a clinical trial of stroke. Clin Neurol Neurosurg. 2013;115:1003-1008.
2. Honmou O, Houkin K, Matsunaga T, etal. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain. 2011;134:1790-1807.
3. Blanquer M, Moraleda JM, Iniesta F, etal. Neurotrophic bone marrow cellular nests prevent spinal motoneuron degeneration in amyotrophic lateral sclerosis patients: a pilot safety study. Stem Cells. 2012;30: 1277-1285.
4. Mazzini L, Ferrero I, Luparello V, etal. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a Phase I clinical trial. Exp Neurol. 2010;223:229-237.
5. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, etal. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010;67:1187-1194.
6. Kallur T, Farr TD, Böhm-Sturm P, etal. Spatio-temporal dynamics, differentiation and viability of human neural stem cells after implantation into neonatal rat brain. Eur J Neurosci. 2011;34:382-393.
7. Riley J, Federici T, Polak M, etal. Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I safety trial, technical note, and lumbar safety outcomes. Neurosurgery. 2012;71:405-416.
8. Moviglia GA, Moviglia-Brandolino MT, Varela GS, etal. Feasibility, safety, and preliminary proof of principles of autologous neural stem cell treatment combined with T-cell vaccination for ALS patients. Cell Transplant. 2012;21:Suppl 1:S57-S63.
9. Puttonen KA, Ruponen M, Kauppinen R, Wojciechowski S, Hovatta O, Koistinaho J. Improved method of producing human neural progenitor cells of high purity and in large quantities from pluripotent stem cells for transplantation studies. Cell Transplant. 2013;22:1753-1766.
10. Mine Y, Tatarishvili J, Oki K, etal. Grafted human neural stem cells enhance several steps of endogenous neurogenesis and improve behavioral recovery after middle cerebral artery occlusion in rats. Neurobiol Dis. 2013;52:191-203.
11. Detante O, Valable S, de Fraipont F, etal. Magnetic resonance imaging and fluorescence labeling of clinical-grade mesenchymal stem cells without impacting their phenotype: study in a rat model of stroke. Stem Cells Transl Med. 2012;1:333-341.
12. McFadden C, Mallett CL, Foster PJ. Labeling of multiple cell lines using a new iron oxide agent for cell tracking by MRI. Contrast Media Mol Imaging. 2011;6:515-522.
13. Loebinger MR, Kyrtatos PG, Turmaine M, etal. Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Res. 2009; 69:8862-8867.
14. Zhang Z, Jiang Q, Jiang F, etal. In vivo magnetic resonance imaging tracks adult neural progenitor cell targeting of brain tumor. Neuroimage. 2004;23:281-287.
15. Berry CC, Wells S, Charles S, etal. Dextran and albumin derivatised iron oxide nanoparticles: influence on fibroblasts in vitro. Biomaterials. 2003;24:4551-4557.
16. Reddy AM, Kwak BK, Shim HJ, etal. In vivo tracking of mesenchymal stem cells labeled with a novel chitosan-coated superparamagnetic iron oxide nanoparticles using 3.0T MRI. J Korean Med Sci. 2010;25: 211-219.
17. Berman SC, Galpoththawela C, Gilad AA, etal. Long-term MR cell tracking of neural stem cells grafted in immunocompetent versus immunodeficient mice reveals distinct differences in contrast between live and dead cells. Magn Reson Med. 2011;65:564-574.
18. Addicott B, Willman M, Rodriguez J, etal. Mesenchymal stem cell labeling and in vitro MR characterization at 1.5 T of new SPIO contrast agent: Molday ION Rhodamine-B. Contrast Media Mol Imaging. 2010;6:7-18.
19. Ren Z, Wang J, Zou C, etal. Labeling of cynomolgus monkey bone marrow-derived mesenchymal stem cells for cell tracking by multimodality imaging. Sci China Life Sci. 2011;54:981-987.
20. Wunderbaldinger P, Josephson L, Weissleder R. Crosslinked iron oxides (CLIO): a new platform for the development of targeted MR contrast agents. Acad Radiol. 2002;9:Suppl 2:S304-S306.
21. Messmer K, Shen W-B, Remington M, etal. Induction of neural differentiation by the transcription factor NeuroD2. Int J Dev Neurosci. 2012;30:105-112.
22. Miyoshi S, Flexman JA, Cross DJ, etal. Transfection of neuroprogenitor cells with iron nanoparticles for magnetic resonance imaging tracking: cell viability, differentiation, and intracellular localization. Mol Imaging Biol. 2005;7:286-295.
23. Matuszewski L, Persigehl T, Wall A, etal. Cell tagging with clinically approved iron oxides: feasibility and effect of lipofection, particle size, and surface coating on labeling efficiency. Radiology. 2005;235: 155-161.
24. Arbab AS, Jordan EK, Wilson LB, etal. In vivo trafficking and targeted delivery of magnetically labeled stem cells. Hum Gene Ther. 2004;15:351-360.